135 related articles for article (PubMed ID: 12906753)
1. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine.
Berggren S; Lennernäs P; Ekelund M; Weström B; Hoogstraate J; Lennernäs H
J Pharm Pharmacol; 2003 Jul; 55(7):963-72. PubMed ID: 12906753
[TBL] [Abstract][Full Text] [Related]
2. Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro.
Tanaka E; Nakamura T; Inomata S; Honda K
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):181-3. PubMed ID: 16445592
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.
Oda Y; Furuichi K; Tanaka K; Hiroi T; Imaoka S; Asada A; Fujimori M; Funae Y
Anesthesiology; 1995 Jan; 82(1):214-20. PubMed ID: 7832304
[TBL] [Abstract][Full Text] [Related]
4. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
Ekström G; Gunnarsson UB
Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
[TBL] [Abstract][Full Text] [Related]
5. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.
Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):653-7. PubMed ID: 12610740
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children.
Aarons L; Sadler B; Pitsiu M; Sjövall J; Henriksson J; Molnár V
Br J Anaesth; 2011 Sep; 107(3):409-24. PubMed ID: 21693469
[TBL] [Abstract][Full Text] [Related]
7. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.
Berggren S; Hoogstraate J; Fagerholm U; Lennernäs H
Eur J Pharm Sci; 2004 Mar; 21(4):553-60. PubMed ID: 14998587
[TBL] [Abstract][Full Text] [Related]
8. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A.
Gantenbein M; Attolini L; Bruguerolle B; Villard PH; Puyoou F; Durand A; Lacarelle B; Hardwigsen J; Le-Treut YP
Drug Metab Dispos; 2000 Apr; 28(4):383-5. PubMed ID: 10725304
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ropivacaine in patients with chronic renal failure.
Pere PJ; Ekstrand A; Salonen M; Honkanen E; Sjövall J; Henriksson J; Rosenberg PH
Br J Anaesth; 2011 Apr; 106(4):512-21. PubMed ID: 21307007
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
[TBL] [Abstract][Full Text] [Related]
11. Effect of propofol on ropivacaine metabolism in human liver microsomes.
Osaka Y; Inomata S; Tanaka E; Nakamura T; Honda K; Miyabe M; Toyooka H; Tanaka M
J Anesth; 2006; 20(1):60-3. PubMed ID: 16421682
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of ropivacaine in humans.
Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
[TBL] [Abstract][Full Text] [Related]
13. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
14. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat.
Li LY; Amidon GL; Kim JS; Heimbach T; Kesisoglou F; Topliss JT; Fleisher D
J Pharmacol Exp Ther; 2002 May; 301(2):586-93. PubMed ID: 11961060
[TBL] [Abstract][Full Text] [Related]
15. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine.
Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2001 Oct; 70(4):344-50. PubMed ID: 11673750
[TBL] [Abstract][Full Text] [Related]
16. [Permeabilities of rebamipide via different intestinal mucosa in the diffusion chamber in vitro].
Li GF; Wang CX; Yan Y; Kishimoto N; Yamamoto A
Yao Xue Xue Bao; 2008 Mar; 43(3):314-7. PubMed ID: 18630271
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block.
Pere P; Salonen M; Jokinen M; Rosenberg PH; Neuvonen PJ; Haasio J
Anesth Analg; 2003 Feb; 96(2):563-9, table of contents. PubMed ID: 12538213
[TBL] [Abstract][Full Text] [Related]
18. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
19. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column.
Arvidsson T; Bruce HF; Halldin MM
Chirality; 1995; 7(4):272-7. PubMed ID: 7640170
[TBL] [Abstract][Full Text] [Related]
20. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
